Tissue penetration of antimicrobials: Difference between revisions

From IDWiki
No edit summary
No edit summary
Line 10: Line 10:
! colspan="7" |Antibiotics: β-Lactams
! colspan="7" |Antibiotics: β-Lactams
|-
|-
| rowspan="2" |Penicillins
| rowspan="3" |Penicillins
|β-lactamase inhibitors
|β-lactamase inhibitors
|
|
| style="text-align:center" |
| style="text-align:center" |–
|
|
|
|
Line 23: Line 23:
|
|
|
|
| style="text-align:center" |
| style="text-align:center" |–
|-
|-
|[[piperacillin-tazobactam]]
| rowspan="4" |Cephalosporins
|
|
|
| +†
|
|-
| rowspan="5" |Cephalosporins
|first-generation cephalosporins
|first-generation cephalosporins
|
|
| style="text-align:center" |
| style="text-align:center" |–
|
|
|
|
| style="text-align:center" |
| style="text-align:center" |–
|-
|-
|second-generation cephalosporins
|second-generation cephalosporins
|
|
| style="text-align:center" |
| style="text-align:center" |–
|
|
|
|-
|third-generation cephalosporins
|
|
|
|
|
| +†
|
|
|-
|-
Line 57: Line 71:
|[[cephamycins]]
|[[cephamycins]]
|
|
| style="text-align:center" |
| style="text-align:center" |–
|
|
|
|
Line 67: Line 81:
|
|
|
|
| style="text-align:center" |
| style="text-align:center" |–
|-
|-
|Carbapenems
|Carbapenems
Line 85: Line 99:
|
|
|
|
| style="text-align:center" |
| style="text-align:center" |–
|-
|-
|Chloramphenicol
|Chloramphenicol
Line 98: Line 112:
|
|
|
|
| style="text-align:center" | –?
| style="text-align:center" |–?
|
|
| style="text-align:center" | +
| style="text-align:center" | +
Line 106: Line 120:
|[[clindamycin]]
|[[clindamycin]]
|
|
| style="text-align:center" |
| style="text-align:center" |–
|
|
|
|
Line 114: Line 128:
|[[macrolides]]
|[[macrolides]]
|
|
| style="text-align:center" |
| style="text-align:center" |–
|
|
| style="text-align:center" | +
| style="text-align:center" | +
Line 121: Line 135:
|Nitrofurans
|Nitrofurans
|[[nitrofurantoin]]
|[[nitrofurantoin]]
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" | +
| style="text-align:center" | +
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |
| style="text-align:center" |–
|-
|-
|Nitroimidazoles
|Nitroimidazoles
Line 148: Line 162:
|
|
|
|
| style="text-align:center" |
| style="text-align:center" |–
|
|
|-
|-
Line 154: Line 168:
|[[tetracyclines]]
|[[tetracyclines]]
|
|
| style="text-align:center" |
| style="text-align:center" |–
|
|
| style="text-align:center" | +
| style="text-align:center" | +
Line 176: Line 190:
| style="text-align:center" | +
| style="text-align:center" | +
|}
|}

* † if inflammation present

[[Category:Antimicrobials]]
[[Category:Antimicrobials]]

Revision as of 16:23, 24 August 2020

Class Antimicrobial Blood CNS Urine Prostate Necrotic
Antibiotics: β-Lactams
Penicillins β-lactamase inhibitors
ampicillin +
piperacillin-tazobactam +†
Cephalosporins first-generation cephalosporins
second-generation cephalosporins
third-generation cephalosporins +†
cefepime +
ceftazidime + +
Cephamycins cephamycins
cefoxitin
Carbapenems imipenem +
Antibiotics: Non-β-Lactams
Aminoglycosides
Chloramphenicol chloramphenicol +
Fluoroquinolones –? + +
Lincosamides clindamycin +
Macrolides macrolides +
Nitrofurans nitrofurantoin +
Nitroimidazoles metronidazole +
Rifamycins rifampin +
Sulfonamides sulfamethoxazole
Tetracyclines tetracyclines +
doxycycline +
Antifungals
Azoles fluconazole +
  • † if inflammation present

References

  1. ^  Cornelia B. Landersdorfer, Jürgen B. Bulitta, Martina Kinzig, Ulrike Holzgrabe, Fritz Sörgel. Penetration of Antibacterials into Bone. Clinical Pharmacokinetics. 2009;48(2):89-124. doi:10.2165/00003088-200948020-00002.